Continuous antioxidant drug exposure: a bridge from ideal world to real world of therapy for amyotrophic lateral sclerosis

Jun Wang; Xin-Fu Zhou; Yan-Jiang Wang

doi:10.1093/lifemedi/lnac042

Life Medicine ›› 2023, Vol. 2 ›› Issue (1) :1 DOI: 10.1093/lifemedi/lnac042

News & Opinion

Continuous antioxidant drug exposure: a bridge from ideal world to real world of therapy for amyotrophic lateral sclerosis

Jun Wang ¹^,²
, Xin-Fu Zhou ³^,^†
, Yan-Jiang Wang ¹^,²^,^†

Author information +

History +

PDF (226KB)

Cite this article

Download citation ▾

Jun Wang, Xin-Fu Zhou, Yan-Jiang Wang. Continuous antioxidant drug exposure: a bridge from ideal world to real world of therapy for amyotrophic lateral sclerosis. Life Medicine, 2023, 2(1): 1 DOI:10.1093/lifemedi/lnac042

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Ferrante RJ, Browne SE, Shinobu LA, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem. 1997;69:2064–74.

[2]	Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610–7.

[3]	Writing G, Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.

[4]	Witzel S, Maier A, Steinbach R, et al. Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022;79:121–30.

[5]	Jiao SS, Yao XQ, Liu YH, et al. Edaravone alleviates Alzheimer’s disease-type pathologies and cognitive deficits. Proc Natl Acad Sci USA. 2015;112:5225–30.